| Filed On | Filing |
|---|---|
| 04 Nov 2024 |
8-K/A: Costs Associated with Exit or Disposal Activities
As previously announced, on August 10, 2024, the Board of Directors (the “Board”) of the Company approved a plan to suspend new internal investment in the development of izokibep in hidradenitis suppurativa (“HS”), psoriatic arthritis (“... |
| 28 May 2024 |
8-K/A: Departure/Election of Directors or Officers; Compensation
Chief Executive Officer Succession and Board of Director Changes |
Loading...
